 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| AGMB-447 / AgomAb Therapeutics
New P1 trial: Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF (clinicaltrials.gov) - Dec 26, 2023
P1, N=76, Recruiting, Sponsor: Agomab Spain S.L.